FR2976807B1 - Composition pharmaceutique pour le traitement de la dependance chez l'etre humain - Google Patents

Composition pharmaceutique pour le traitement de la dependance chez l'etre humain

Info

Publication number
FR2976807B1
FR2976807B1 FR1155631A FR1155631A FR2976807B1 FR 2976807 B1 FR2976807 B1 FR 2976807B1 FR 1155631 A FR1155631 A FR 1155631A FR 1155631 A FR1155631 A FR 1155631A FR 2976807 B1 FR2976807 B1 FR 2976807B1
Authority
FR
France
Prior art keywords
dependence
treatment
pharmaceutical composition
human beings
beings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1155631A
Other languages
English (en)
Other versions
FR2976807A1 (fr
Inventor
Philippe Bernard
Fabrice Trovero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Key OBS
Greenpharma SAS
Original Assignee
Key OBS
Greenpharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Key OBS, Greenpharma SAS filed Critical Key OBS
Priority to FR1155631A priority Critical patent/FR2976807B1/fr
Priority to RU2014101958/15A priority patent/RU2605283C2/ru
Priority to PCT/FR2012/051443 priority patent/WO2012175894A1/fr
Priority to UAA201400601A priority patent/UA111364C2/uk
Publication of FR2976807A1 publication Critical patent/FR2976807A1/fr
Application granted granted Critical
Publication of FR2976807B1 publication Critical patent/FR2976807B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1155631A 2011-06-24 2011-06-24 Composition pharmaceutique pour le traitement de la dependance chez l'etre humain Active FR2976807B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1155631A FR2976807B1 (fr) 2011-06-24 2011-06-24 Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
RU2014101958/15A RU2605283C2 (ru) 2011-06-24 2012-06-25 Фармацевтическая композиция для лечения зависимости у людей
PCT/FR2012/051443 WO2012175894A1 (fr) 2011-06-24 2012-06-25 Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
UAA201400601A UA111364C2 (uk) 2011-06-24 2012-06-25 Фармацевтична композиція для лікування фізичної залежності в людини

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1155631A FR2976807B1 (fr) 2011-06-24 2011-06-24 Composition pharmaceutique pour le traitement de la dependance chez l'etre humain

Publications (2)

Publication Number Publication Date
FR2976807A1 FR2976807A1 (fr) 2012-12-28
FR2976807B1 true FR2976807B1 (fr) 2013-07-05

Family

ID=46579182

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1155631A Active FR2976807B1 (fr) 2011-06-24 2011-06-24 Composition pharmaceutique pour le traitement de la dependance chez l'etre humain

Country Status (4)

Country Link
FR (1) FR2976807B1 (fr)
RU (1) RU2605283C2 (fr)
UA (1) UA111364C2 (fr)
WO (1) WO2012175894A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017296A1 (fr) * 2013-11-28 2015-08-14 Greenpharma Sas Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
FR3138303A1 (fr) * 2022-07-26 2024-02-02 Kinnov Therapeutics Composition pharmaceutique pour le traitement du syndrome de stress post-traumatique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2190392C1 (ru) * 2001-09-14 2002-10-10 Нестерук Владимир Викторович Фармацевтическая композиция на основе доксазозина
FR2873294B1 (fr) * 2004-07-26 2008-05-09 Greenpharma Sa Sa Association de medicaments
WO2006017861A2 (fr) * 2004-08-13 2006-02-16 Omeros Corporation Traitement de l'accoutumance à la méthamphétamine et réduction de la prise de méthamphétamine au moyen d'antagonistes de la sérotonine
FR2954699B1 (fr) * 2009-12-30 2012-01-20 Greenpharma Sas Composition pharmaceutique pour le traitement de la dependance a l'alcool

Also Published As

Publication number Publication date
WO2012175894A1 (fr) 2012-12-27
RU2605283C2 (ru) 2016-12-20
UA111364C2 (uk) 2016-04-25
FR2976807A1 (fr) 2012-12-28
RU2014101958A (ru) 2015-07-27

Similar Documents

Publication Publication Date Title
FR22C1062I2 (fr) Thérapie de remplacement enzymatique d'escalade de doses pour le traitement du déficit en sphingomyélinase acide
EA201991484A1 (ru) Лекарственные формы энзалутамида
FR20C1026I1 (fr) Ciclesonide pour le traitement de maladies des voies respiratoires chez les chevaux
EP3686200A3 (fr) Composés hétérocycles bicycliques et leurs utilisations en thérapie
IL237369A0 (en) Methods for treating Alzheimer's disease and pharmaceutical compositions thereof
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2013002341A1 (es) Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros
PL2600865T3 (pl) Związek użyteczny do leczenia chorób, w których pośredniczy mutacja nonsensowna oraz kompozycje farmaceutyczne zawierające wymieniony związek
IL232325A0 (en) 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
EP3628326C0 (fr) Méthodes et substances permettant de traiter la maladie de pompe
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
FR2962650B1 (fr) Composition d'immunoglobulines humaines concentrees
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
FR2995784B1 (fr) Composition cosmetique sous forme d'emulsion et procede de traitement cosmetique
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
DE102009018133A8 (de) Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
PL2903608T3 (pl) Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
FR2963237B1 (fr) Nouvelle composition pharmaceutique utile pour prevenir ou traiter l'hypotension arterielle peroperatoire chez l'etre humain
FR2976807B1 (fr) Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
FR2992219B1 (fr) Composition pour le traitement de l'hypocalcemie chez les ruminants
IL239078A0 (en) Protein for use in the treatment of eye diseases
IT1404270B1 (it) Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid
FR2954699B1 (fr) Composition pharmaceutique pour le traitement de la dependance a l'alcool
FR2953723B1 (fr) Composition pharmaceutique destinee au traitement des pathologies orthopediques

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14